GHRP-2 vs HGH (Somatropin)
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Growth Hormone Releasing Peptide 2, Pralmorelin
GHRP-2 (generic name pralmorelin) is a synthetic hexapeptide growth hormone secretagogue and a second-generation cousin of GHRP-6. It prompts the pituitary to release growth hormone and is the one peptide in this family with an actual regulatory approval: it is licensed in Japan as a diagnostic agent for growth hormone deficiency. Outside that narrow diagnostic use it has no approval and is sold elsewhere only as a research compound.
Also: Somatropin, Human Growth Hormone
Human growth hormone is the real thing rather than a secretagogue: a 191-amino-acid protein identical to what your pituitary makes, produced recombinantly since the 1980s. It is a properly approved medicine for growth hormone deficiency, and it is also the most misused compound in this entire space. Almost everything you read about HGH for anti-aging or physique traces back to a single small 1990 study whose own author later disowned how it was used.
Key Comparison Insights
- HGH (Somatropin) is FDA approved, while GHRP-2 remains in research stages.
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- HGH (Somatropin) has stronger research evidence (FDA Approved) compared to GHRP-2 (Human Trials).
Detailed Comparison
| Attribute | GHRP-2 | HGH (Somatropin) |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Like GHRP-6, GHRP-2 is an agonist at the ghrelin / growth hormone secretagogue receptor (GHS-R1a). Binding that receptor in the pituitary and hypothalamus drives a pulse of growth hormone release. It was designed to be more potent and somewhat cleaner than GHRP-6, with a milder effect on appetite, though it still acts on the ghrelin system so it is not free of off-target hormonal effects. Because it works upstream of the pituitary rather than replacing GH directly, the GH release it causes is still subject to the body's own feedback brakes such as somatostatin. | HGH binds the growth hormone receptor, mostly in the liver, which triggers IGF-1 release. IGF-1 does much of the work people associate with growth hormone: it drives cell growth, protein synthesis and cartilage growth. HGH itself acts directly on fat tissue, encouraging lipolysis, and it opposes insulin, which is why higher doses push blood sugar up and can create insulin resistance over time. The direct-versus-IGF-1 split matters practically: effects on fat come quickly and are largely direct, while effects on muscle and connective tissue are slower and IGF-1 mediated. This is also why HGH and IGF-1 LR3 are not interchangeable despite being linked. |
| Common Dosing | 100-300 mcg 2-3x daily 2-3x daily | 0.15-0.3 mg daily (clinical) or 2-4 IU daily (community) Once daily, typically evening |
| Administration | Subcutaneous injection | Subcutaneous injection, usually daily, commonly in the evening to mimic natural nocturnal release |
| Typical Duration | 8-12 weeks | Clinical use is ongoing and monitored. Community cycles are typically reported as 3-6 months. |
| Best Time to Take | Before bed or morning (fasted) | Evening, before bed |
Possible Side Effects May vary by individual |
|
|
| Research Summary | GHRP-2 has genuine human data behind its diagnostic role. In Japan it reached phase II trials and was approved as pralmorelin (intravenous) to test for growth hormone deficiency, including in children with short stature, making it the only GH secretagogue in this class with any regulatory approval. A published human pharmacology study detected unchanged GHRP-2 and its metabolite AA-3 in the urine of ten male volunteers given the drug intravenously, work driven largely by anti-doping testing because GHRP-2 is banned in sport. What it does NOT have is solid controlled-trial evidence for the body-composition, anti-aging, or recovery uses it is marketed for online. So the honest picture is a real, approved diagnostic tool in one country, with everything beyond that being off-label or unproven research use. | For diagnosed growth hormone deficiency the evidence is solid and decades deep: recombinant HGH restores body composition, bone density and quality of life in adults with genuine deficiency, and it is approved for that. For everyone else the picture is far weaker. The famous Rudman study in the New England Journal of Medicine in 1990 gave HGH to 12 older men for six months and reported gains in lean mass and reductions in fat, and that single small trial launched an entire anti-aging industry. It had no functional strength or performance endpoints, it was not designed to assess safety, and Rudman maintained until his death in 1994 that it carried no anti-aging implications. NEJM published an editorial in 2003 criticizing the industry that had grown up around citing it. Subsequent reviews of HGH in healthy older adults have found modest body composition changes alongside frequent side effects, with no demonstrated benefit to strength, function or longevity. Long-term supraphysiologic use carries real risks including insulin resistance and, at sustained high doses, acromegaly-like changes. |
Frequently Asked Questions: GHRP-2 vs HGH (Somatropin)
What is the difference between GHRP-2 and HGH (Somatropin)?
GHRP-2 is a growth hormone peptide that ghrp-2 (generic name pralmorelin) is a synthetic hexapeptide growth hormone secretagogue and a second-generation cousin of ghrp-6. it prompts the pituitary to release growth hormone and is the one peptide in this family with an actual regulatory approval: it is licensed in japan as a diagnostic agent for growth hormone deficiency. outside that narrow diagnostic use it has no approval and is sold elsewhere only as a research compound. HGH (Somatropin) is a growth hormone peptide that human growth hormone is the real thing rather than a secretagogue: a 191-amino-acid protein identical to what your pituitary makes, produced recombinantly since the 1980s. it is a properly approved medicine for growth hormone deficiency, and it is also the most misused compound in this entire space. almost everything you read about hgh for anti-aging or physique traces back to a single small 1990 study whose own author later disowned how it was used. The main differences lie in their mechanisms of action and clinical applications.
Which is better, GHRP-2 or HGH (Somatropin)?
Neither is universally "better" - the choice depends on your specific goals. GHRP-2 is typically used for growth hormone purposes, while HGH (Somatropin) is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can GHRP-2 and HGH (Somatropin) be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using GHRP-2 and HGH (Somatropin) together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.